Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Mouse (Murine) EPH Receptor B4 Antikörper:
anti-Human EPH Receptor B4 Antikörper:
anti-Rat (Rattus) EPH Receptor B4 Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Mouse (Murine) Polyclonal EPH Receptor B4 Primary Antibody für CyTOF, FACS - ABIN4899282
Foster, Gordon, Cardenas, Veiga-Fernandes, Makinen, Grigorieva, Wilkinson, Blackburn, Richie, Manley, Adams, Kioussis, Coles: EphB-ephrin-B2 interactions are required for thymus migration during organogenesis. in Proceedings of the National Academy of Sciences of the United States of America 2010
Show all 17 Pubmed References
Human Polyclonal EPH Receptor B4 Primary Antibody für CyTOF, FACS - ABIN4899281
Boyer-Di Ponio, El-Ayoubi, Glacial, Ganeshamoorthy, Driancourt, Godet, Perrière, Guillevic, Couraud, Uzan: Instruction of circulating endothelial progenitors in vitro towards specialized blood-brain barrier and arterial phenotypes. in PLoS ONE 2014
Show all 6 Pubmed References
Human Monoclonal EPH Receptor B4 Primary Antibody für ELISA, WB - ABIN1724713
Jiménez-Vega, Yepiz-Plascencia, Söderhäll, Vargas-Albores: A single WAP domain-containing protein from Litopenaeus vannamei hemocytes. in Biochemical and biophysical research communications 2004
Show all 3 Pubmed References
Human Monoclonal EPH Receptor B4 Primary Antibody für IHC, ELISA - ABIN969107
Chrencik, Brooun, Recht, Kraus, Koolpe, Kolatkar, Bruce, Martiny-Baron, Widmer, Pasquale, Kuhn: Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity. in Structure (London, England : 1993) 2006
Show all 2 Pubmed References
Human Monoclonal EPH Receptor B4 Primary Antibody für IHC, ELISA - ABIN966076
Kubota: [What is drug-epidemiology?]. in Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 2007
Show all 3 Pubmed References
Human Polyclonal EPH Receptor B4 Primary Antibody für IHC (p), WB - ABIN391924
Steinle, Meininger, Forough, Wu, Wu, Granger: Eph B4 receptor signaling mediates endothelial cell migration and proliferation via the phosphatidylinositol 3-kinase pathway. in The Journal of biological chemistry 2002
Show all 5 Pubmed References
Human Monoclonal EPH Receptor B4 Primary Antibody für IF, ELISA - ABIN966075
Wu, Suo, Risberg, Karlsson, Villman, Nesland: Expression of Ephb2 and Ephb4 in breast carcinoma. in Pathology oncology research : POR 2004
Show all 2 Pubmed References
Human Monoclonal EPH Receptor B4 Primary Antibody für ICC, ELISA - ABIN969108
Tachibana, Tonomoto, Hyakudomi, Hyakudomi, Hattori, Ueda, Kinugasa, Yoshimura: Expression and prognostic significance of EFNB2 and EphB4 genes in patients with oesophageal squamous cell carcinoma. in Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2007
Human Polyclonal EPH Receptor B4 Primary Antibody für ELISA - ABIN261662
Kumar, Masood, Spannuth, Singh, Scehnet, Kleiber, Jennings, Deavers, Krasnoperov, Dubeau, Weaver, Sood, Gill: The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. in British journal of cancer 2007
Mouse (Murine) Monoclonal EPH Receptor B4 Primary Antibody für IA, IHC (fro) - ABIN2191850
Huang, Yamada, Kidoya, Naito, Nagahama, Kong, Katoh, Li, Ueno, Takakura: EphB4 overexpression in B16 melanoma cells affects arterial-venous patterning in tumor angiogenesis. in Cancer research 2007
EPHB4 is a critical regulator of early lymphatic vascular development; mutations in the gene can cause an autosomal dominant form of LRHF that is associated with a high mortality rate
These results identify EPHB4/ephrin B2 (zeige EFNB2 Antikörper) signaling as critical to Hematopoietic stem and progenitor cells mobilization from bone marrow
EphB4 plays an irreplaceable role in bone regeneration in an inflammatory microenvironment, whereas the functional loss of ephrinB2 (zeige EFNB2 Antikörper) can be effectively compensated, most possibly by other ephrins with similar chemical structures
Eph (zeige EPHA1 Antikörper)-B4 stimulates eNOS (zeige NOS3 Antikörper) phosphorylation in vitro and may mediate vein graft adaptation by regulation of eNOS (zeige NOS3 Antikörper) activity in vivo.
These data indicate that ephrinB2 (zeige EFNB2 Antikörper)/EphB4 signaling within the osteoblast lineage is required for late stages of osteoblast differentiation.
EphB4 promotes endochondral ossification while inhibiting osteoclast development during callus formation.
Selective inhibition of EphB4 using a functional blocking antibody results in defective lymphatic valve development.
Overexpression of bone-specific Ephb4 clearly demonstrated prevention of the development and/or progression of fibrosis in OA synovial membrane
EphB4-forward signaling plays a crucial role in the development of cardiac progenitor cells.
EPHB4 plays an essential role in regulating small artery contractility and blood pressure
Inhibition of EphB4 forward signaling using soluble EphB4 protein fused (zeige AXIN1 Antikörper) with murine serum albumin (zeige ALB Antikörper) failed to affect eRMS model tumor progression, but did moderately slow progression in murine aRMS
EPHB4 mutations were identified in patients with multifocal capillary malformation with arteriovenous malformations.
EPHB4 is a critical regulator of early lymphatic vascular development; mutations in the gene can cause an autosomal dominant form of lymphatic-related hydrops fetalis that is associated with a high mortality rate
The expression of EPHB4 was increased in gastric cancer and increased EPHB4 expression was correlated with poor survival. Knockdown of EPHB4 promoted adhesion and exerted diverse effects on migration of gastric cancer cells.
EphB4 protein acts as a tumour promoter associated with proliferation, invasion, and angiogenesis, and may be used as a potential colorectal cancer (CRC (zeige CALR Antikörper)) therapeutic target.
Study illustrates that aberrant activation of EphB4/ephrinB2 (zeige EFNB2 Antikörper) may mediate chronic myeloid leukemia (zeige BCL11A Antikörper) resistance involved in cytoskeletal proteins.
both EphA2 (zeige EPHA2 Antikörper) and EphB4 show potential as target for image-guided colorectal cancer surgery, but EphB4 seems to have the best characteristics with respect to tumor/normal mucosa distribution.
Survival analysis showed that the non-small cell lung carcinoma patients with enhanced expression of CK7 (zeige KRT7 Antikörper), ELF3 (zeige ELF3 Antikörper), EGFR (zeige EGFR Antikörper), and EphB4 mRNA in peripheral blood leukocytes had poorer disease-free survival and overall survival than those without.
Enhanced EphB4 expression was significantly associated with Thyroid Lesions.
LISA method may be considered rapid and sensitive enough to detect even low levels of total and phosphorylated EphB4 Cost-effectiveness of this method for the detection of differential expression of EphB4 proteins in clinics is also noticeable.
Ephrin receptors and their ligands, the ephrins, mediate numerous developmental processes, particularly in the nervous system. Based on their structures and sequence relationships, ephrins are divided into the ephrin-A (EFNA) class, which are anchored to the membrane by a glycosylphosphatidylinositol linkage, and the ephrin-B (EFNB) class, which are transmembrane proteins. The Eph family of receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. Ephrin receptors make up the largest subgroup of the receptor tyrosine kinase (RTK) family. The protein encoded by this gene binds to ephrin-B2 and plays an essential role in vascular development.
EPH receptor B4
, eph receptor tyrosine kinase
, ephrin receptor EphB4
, ephrin type-B receptor 4-like
, developmental kinase 2
, ephrin type-B receptor 4
, hepatoma transmembrane kinase
, tyrosine kinase MYK-1
, soluble EPHB4 variant 1
, soluble EPHB4 variant 2
, soluble EPHB4 variant 3
, tyrosine-protein kinase TYRO11
, tyrosine-protein kinase receptor HTK